Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes

Yuka Kamijo,Hideto Ishii,Tomohiko Yamamoto,Kunihisa Kobayashi,Hiroyuki Asano,Shunji Miake,Eiichiro Kanda,Hidenori Urata,Masayuki Yoshida

Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes

2019

Yuka Kamijo
Hideto Ishii
Tomohiko Yamamoto
Kunihisa Kobayashi
Hiroyuki Asano
Shunji Miake
Eiichiro Kanda
Hidenori Urata
Masayuki Yoshida

Introduction:Recently, the sodium-glucose cotransporter2 (SGLT2) inhibitor empagliflozin has been shown to lower cardiovascular risk among diabetic patients. It is intriguing that some SGLT2 inhibi...

Keywords:

Lipoprotein
SGLT2 Inhibitor
Medicine
Type 2 diabetes
Internal medicine
Endocrinology
Empagliflozin
Canagliflozin
Lipid metabolism
potential impact

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations